One Wales

We welcome suggestions for medicines to be considered via the One Wales Medicines process from Individual Patient Funding Request (IPFR) panels, Welsh Health Specialised Services Committee (WHSSC), clinicians (ideally through clinical networks), chief pharmacists, formulary pharmacists or medicines and therapeutics committees. The process is driven by identification of unmet clinical need by the service and therefore we cannot accept requests from pharmaceutical companies or from members of the public.

The One Wales Medicines Process, (previously known as the One Wales Interim Commissioning process) was developed in 2015, following a review of the individual patient funding request process. It introduced an alternative route to access a medicine (or medicines) for a clearly defined and specific cohort of patients in the absence of health technology appraisal advice. One Wales decisions are based on the available evidence of clinical effectiveness and cost-effectiveness. Once approved, these interim decisions ensure that there is equitable access to these medicines across NHS Wales. This document explains when this process may be used and how it works.

List of medicines not considered suitable for the One Wales Medicines Process (January 2022)

Equality & Health Impact Assessment for the One Wales Medicines process (updated October 2022)